SCHEMBL7609264

SCHEMBL7609264

CC(C)(C)OC(=O)NC1(CBr)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 1/20 0.37
CTSL P07711 1/20 0.37
APLNR P35414 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
P2RX7 Q99572 1/20 0.36
PPIA P62937 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
GAA P10253 1/20 0.34
CTSK P43235 1/20 0.34
AKT1 P31749 1/20 0.34
CA12 O43570 2/20 0.33
CA14 Q9ULX7 2/20 0.33
EPHX1 P07099 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16937147 0.84 GAA (0.38) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL14173595 0.83 KMT2A (0.38) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL56916 0.83 TDP1 (0.41) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL1752478 0.81 MEN1 (0.37) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL1751859 0.81 P2RX7 (0.38) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL28143048 0.81 MEN1 (0.37) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL24457724 0.80 MEN1 (0.36) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL17553436 0.80 P2RX7 (0.40) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL15297512 0.80 MEN1 (0.37) MEN1KMT2AMAPK1CTSLAPLNR
SCHEMBL23161172 0.80 MEN1 (0.36) MEN1KMT2AMAPK1CTSLAPLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 WO disclosed
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-02-12 US disclosed
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-11-11 US disclosed
EP-4584269-A1 PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR THE TREATMENT OF CANCER Eli Lilly and Company (US) 2025-07-16 EP disclosed
US-20250163022-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-3971187-B1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2025-05-07 EP disclosed
US-20250101034-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2025-03-27 US disclosed
WO-2024227026-A1 HETEROCYCLIC COMPOUNDS AS PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
EP-4452963-A1 PARP1 INHIBITORS Synnovation Therapeutics, Inc. (US) 2024-10-30 EP disclosed
EP-4426704-A1 CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 Skyhawk Therapeutics, Inc. (US) 2024-09-11 EP disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed
WO-2021108023-A1 PENICILLIN-BINDING PROTEIN INHIBITORS VenatoRx Pharmaceuticals, Inc. (US) 2021-06-03 WO disclosed
WO-2020228756-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2020-11-19 WO disclosed
WO-2019154261-A1 PYRIDINE DERIVATIVE RELATED TO KMD5 PATHWAY 南京明德新药研发股份有限公司 2019-08-15 WO disclosed
US-9777020-B2 Furo-3-carboxamide derivatives and methods of use ABBVIE INC. (US) 2017-10-03 US disclosed
EP-3097095-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE AbbVie Inc. (US) 2016-11-30 EP disclosed
CN-104870007-A New antiviral macrocycles SCYNEXIS INC 2015-08-26 CN disclosed
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. 2015-07-30 US disclosed
WO-2015112754-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. (US) 2015-07-30 WO disclosed
EP-1170281-A1 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof LES LABORATOIRES SERVIER (FR) 2002-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101034-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING RBM17, SNRPE, SNRPA1 MEN1 3396/4885KMT2A 3059/4885MAPK1 4181/4885
US-20260042759-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF FAR1, CYP4A11, CYP11B1 MEN1 933/4885KMT2A 2865/4885MAPK1 399/4885
US-20250163022-A1 PARP1 INHIBITORS PARP1, PARP11, PARP12 MEN1 2993/4885KMT2A 740/4885MAPK1 1787/4885
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE NTRK2, MUSK, NTRK3 MEN1 1006/4885KMT2A 2916/4885MAPK1 959/4885
US-12466823-B2 Inhibitor containing bicyclic derivative, preparation method therefor and use thereof RET, REL, GOT1 MEN1 662/4885KMT2A 3392/4885MAPK1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.